Stanley Druckenmiller's position in Alnylam Pharmaceuticals is currently worth $19.6 Million. That's 1.02% of their equity portfolio (23rd largest holding). The first Alnylam Pharmaceuticals trade was made in Q4 2019. Since then Stanley Druckenmiller bought shares three more times and sold shares on two occasions. The stake costed the investor $16.9 Million, netting the investor a gain of 16% so far.